Single-domain adapted antibodies against Chlamydia trachomatis, preserving the development of chlamidic infection in vitro

   
Tillib S.V.1 , Morgunova E.Y.2, Ivanova T.I.1, Koroleva E.A.2, Rutovskaya M.V.1, Zigangirova N.A.2

1. Institute of Gene Biology, Moscow, Russia
2. Gamaleya Institute of Epidemiology and Microbiology, Moscow, Russia
Section: Technologies of Precision Medicine
DOI: 10.18097/PBMC20176305461      PubMed Id: 29080882
Year: 2017  Volume: 63  Issue: 5  Pages: 461-466
The technology for the generating of single-domain recombinant monoclonal antibodies (nanoantibodies) based on the immunization of a camel, cloning of induced sequences encoding single-domain antigen-recognizing fragments of non-canonical camel antibodies, as well as functional selection of clones of nanoantibodies by the phage display method, was used to obtain new effective tools for more efficient diagnostics of Chlamydia infection and to develop new approaches for effective therapy. Two promising nanoantibodies were obtained. They showed effective binding to extracellular and intracellular forms of C. trachomatis, and also had activity that inhibited the development of chlamydial infection in vitro.
Download PDF:
Reference:

Tillib S.V., Morgunova E.Y., Ivanova T.I., Koroleva E.A., Rutovskaya M.V., Zigangirova N.A. (2017) Biomeditsinskaya khimiya, 63(5), 461-466.
References  
 2019 (vol 65)
 2018 (vol 64)
 2017 (vol 63)
 2016 (vol 62)
 2015 (vol 61)
 2014 (vol 60)
 2013 (vol 59)
 2012 (vol 58)
 2011 (vol 57)
 2010 (vol 56)
 2009 (vol 55)
 2008 (vol 54)
 2007 (vol 53)
 2006 (vol 52)
 2005 (vol 51)
 2004 (vol 50)
 2003 (vol 49)